IPC Publication
A
HUMAN NECESSITIES
HEALTH; LIFE-SAVING; AMUSEMENT
A61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J 3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

Note(s) [2006.01]

  • This subclass covers the following subject matter, whether set forth as a composition (mixture), process of preparing the composition or process of treating using the composition:
    • Drug or other biological compositions which are capable of:
      • preventing, alleviating, treating or curing abnormal or pathological conditions of the living body by such means as destroying a parasitic organism, or limiting the effect of the disease or abnormality by chemically altering the physiology of the host or parasite (biocides A01N 25/00-A01N 65/00);
      • maintaining, increasing, decreasing, limiting, or destroying a physiological body function, e.g. vitamin compositions, sex sterilants, fertility inhibitors, growth promotors, or the like (sex sterilants for invertebrates, e.g. insects, A01N; plant growth regulators A01N 25/00-A01N 65/00);
      • diagnosing a physiological condition or state by an in vivo test, e.g. X-ray contrast or skin patch test compositions (measuring or testing processes involving enzymes or micro-organisms C12Q; in vitro testing of biological material, e.g. blood, urine, G01N, e.g. G01N 33/48);
    • Body treating compositions generally intended for deodorising, protecting, adorning or grooming a body, e.g. cosmetics, dentifrices, tooth filling materials.
  • Attention is drawn to the definitions of groups of chemical elements following the title of section C.
  • Attention is drawn to the notes in class C07, for example the notes following the title of the subclass C07D, setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds in A61K.
  • In this subclass, with the exception of group A61K 8/00, the last place priority rule is applied, i.e. at each hierarchical level, in the absence of an indication to the contrary, classification is made in the last appropriate place.
  • Therapeutic activity of medicinal preparations is further classified in subclass A61P.

Note(s) [2006.01]

  • A composition, i.e. a mixture of two or more components, is classified in the last of groups A61K 31/00-A61K 47/00 that provides for at least one of these components. The components may be single compounds or other single ingredients.
  • Any part of a composition which is not identified by the classification according to Note (1), and which itself is determined to be novel and non-obvious, must also be classified in the last appropriate place in groups A61K 31/00-A61K 47/00. The part can be either a single component or a composition in itself.
  • Any part of a composition which is not identified by the classification according to Note (1) or (2), and which is considered to represent information of interest for search, may also be classified in the last appropriate place in groups A61K 31/00-A61K 47/00. This can for example be the case when it is considered of interest to enable searching of compositions using a combination of classification symbols. Such non-obligatory classification should be given as "additional information".
A61K 31/00
Medicinal preparations containing organic active ingredients [2006.01]

Note(s) [7]

  • Organic active compounds forming salts or complexes with heavy metals are not classified in groups A61K 31/28, A61K 31/555 or A61K 31/7135, unless explicit indication to the contrary is made, e.g. hemin A61K 31/555.
  • In this group, the expressions "containing further heterocyclic rings" and "condensed with heterocyclic rings" also cover compounds having two or more identical heterocyclic rings.
A61K 31/01
•
Hydrocarbons [2006.01]
A61K 31/015
•
•
carbocyclic [2006.01]
A61K 31/02
•
Halogenated hydrocarbons [2006.01]
A61K 31/025
•
•
carbocyclic [2006.01]
A61K 31/03
•
•
•
aromatic [2006.01]
A61K 31/035
•
•
having aliphatic unsaturation [2006.01]
A61K 31/04
•
Nitro compounds [2006.01]
A61K 31/045
•
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates (hydroperoxides A61K 31/327) [2006.01]
A61K 31/047
•
•
having two or more hydroxy groups, e.g. sorbitol [2006.01]
A61K 31/05
•
•
Phenols [2006.01]
A61K 31/055
•
•
•
the aromatic ring being substituted by halogen [2006.01]
A61K 31/06
•
•
•
the aromatic ring being substituted by nitro groups [2006.01]
A61K 31/065
•
•
Diphenyl-substituted acyclic alcohols [2006.01]
A61K 31/07
•
•
Retinol compounds, e.g. vitamin A (retinoic acids A61K 31/203) [2006.01]
A61K 31/075
•
Ethers or acetals [2006.01]
A61K 31/08
•
•
acyclic, e.g. paraformaldehyde [2006.01]
A61K 31/085
•
•
having an ether linkage to aromatic ring nuclear carbon [2006.01]
A61K 31/09
•
•
•
having two or more such linkages [2006.01]
A61K 31/095
•
Sulfur, selenium or tellurium compounds, e.g. thiols [2006.01]
A61K 31/10
•
•
Sulfides; Sulfoxides; Sulfones [2006.01]
A61K 31/105
•
•
Persulfides (thiuram disulfides A61K 31/145; thiosulfonic acids A61K 31/185) [2006.01]
A61K 31/11
•
Aldehydes [2006.01]
A61K 31/115
•
•
Formaldehyde [2006.01]
A61K 31/12
•
Ketones [2006.01]
A61K 31/121
•
•
acyclic [2006.01]
A61K 31/122
•
•
having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin [2006.01]
A61K 31/125
•
•
•
Camphor; Nuclear substituted derivatives thereof [2006.01]
A61K 31/13
•
Amines, e.g. amantadine (A61K 31/04 takes precedence) [2006.01]
A61K 31/131
•
•
acyclic [2006.01]
A61K 31/132
•
•
having two or more amino groups, e.g. spermidine, putrescine [2006.01]
A61K 31/133
•
•
having hydroxy groups, e.g. sphingosine [2006.01]
A61K 31/135
•
•
having aromatic rings, e.g. methadone [2006.01]
A61K 31/136
•
•
•
having the amino group directly attached to the aromatic ring, e.g. benzeneamine [2006.01]
A61K 31/137
•
•
•
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine [2006.01]
A61K 31/138
•
•
•
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K 31/165; pindolol A61K 31/404; timolol A61K 31/5377) [2006.01]
A61K 31/14
•
•
Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K 31/205) [2006.01]
A61K 31/145
•
•
having sulfur atoms, e.g. thiurams (llinktN—C(S)—S—C(S)—Nrlinkt or llinktN—C(S)—S—S—C(S)—Nrlinkt); Sulfinylamines (—N=SO); Sulfonylamines (—N=SO2) (isothioureas A61K 31/155) [2006.01]
A61K 31/15
•
•
Oximes (llinktC=N—O—); Hydrazines (llinktN—Nrlinkt); Hydrazones (llinktN—N=) [2006.01]
A61K 31/155
•
•
Amidines (fig701), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2) [2006.01]
A61K 31/16
•
Amides, e.g. hydroxamic acids [2006.01]
A61K 31/164
•
•
of a carboxylic acid with an aminoalcohol, e.g. ceramides [2006.01]
A61K 31/165
•
•
having aromatic rings, e.g. colchicine, atenolol, progabide [2006.01]
A61K 31/166
•
•
•
having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol [2006.01]
A61K 31/167
•
•
•
having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol [2006.01]
A61K 31/17
•
•
having the group llinktN—C(O)—Nrlinkt or llinktN—C(S)—Nrlinkt, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K 31/155; sulfonylureas A61K 31/64) [2006.01]
A61K 31/175
•
•
•
having the group fig702, llinktN—C(O)—N=N— or fig703, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof [2006.01]
A61K 31/18
•
•
Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N-group A61K 31/63) [2006.01]
A61K 31/185
•
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K 31/16; peroxy acids A61K 31/327) [2006.01]
A61K 31/19
•
•
Carboxylic acids, e.g. valproic acid (salicylic acid A61K 31/60) [2006.01]
A61K 31/191
•
•
•
Acyclic acids having two or more hydroxy groups, e.g. gluconic acid [2006.01]
A61K 31/192
•
•
•
having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid [2006.01]
A61K 31/194
•
•
•
having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid [2006.01]
A61K 31/195
•
•
•
having an amino group [2006.01]
•
•
•

Note(s) [7]

  • In this group, the expression "amino group" also covers "acyl amino group".
A61K 31/196
•
•
•
•
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil [2006.01]
A61K 31/197
•
•
•
•
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid (carnitine A61K 31/205) [2006.01]
A61K 31/198
•
•
•
•
•
Alpha-amino acids, e.g. alanine, edetic acid (EDTA) (betaine A61K 31/205; proline A61K 31/401; tryptophan A61K 31/405; histidine A61K 31/4172; peptides not degraded to individual amino acids A61K 38/00) [2006.01]
A61K 31/20
•
•
•
having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid [2006.01]
A61K 31/201
•
•
•
•
having one or two double bonds, e.g. oleic or linoleic acid [2006.01]
A61K 31/202
•
•
•
•
having three or more double bonds, e.g. linolenic acid (eicosanoids, e.g. leukotrienes, A61K 31/557) [2006.01]
A61K 31/203
•
•
•
•
Retinoic acids [2006.01]
A61K 31/205
•
•
Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine [2006.01]
A61K 31/21
•
Esters, e.g. nitroglycerine, selenocyanates [2006.01]
A61K 31/215
•
•
of carboxylic acids [2006.01]
A61K 31/216
•
•
•
of acids having aromatic rings, e.g. benactizyne, clofibrate [2006.01]
A61K 31/22
•
•
•
of acyclic acids, e.g. pravastatin [2006.01]
A61K 31/221
•
•
•
•
with compounds having an amino group, e.g. acetylcholine, acetylcarnitine [2006.01]
A61K 31/222
•
•
•
•
with compounds having aromatic groups, e.g. dipivefrine, ibopamine [2006.01]
A61K 31/223
•
•
•
•
of alpha-amino acids [2006.01]
A61K 31/225
•
•
•
•
Polycarboxylic acids [2006.01]
A61K 31/23
•
•
•
•
of acids having a carboxyl group bound to a chain of seven or more carbon atoms [2006.01]
A61K 31/231
•
•
•
•
•
having one or two double bonds [2006.01]
A61K 31/232
•
•
•
•
•
having three or more double bonds, e.g. etretinate [2006.01]
A61K 31/235
•
•
•
having an aromatic ring attached to a carboxyl group [2006.01]
A61K 31/24
•
•
•
•
having an amino or nitro group [2006.01]
A61K 31/245
•
•
•
•
•
Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K 31/60) [2006.01]
A61K 31/25
•
•
•
with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol [2006.01]
A61K 31/255
•
•
of sulfoxy acids or sulfur analogues thereof [2006.01]
A61K 31/26
•
•
Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters [2006.01]
A61K 31/265
•
•
of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid [2006.01]
A61K 31/27
•
•
of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine [2006.01]
A61K 31/275
•
Nitriles; Isonitriles [2006.01]
A61K 31/277
•
•
having a ring, e.g. verapamil [2006.01]
A61K 31/28
•
Compounds containing heavy metals [2006.01]
A61K 31/282
•
•
Platinum compounds [2006.01]
A61K 31/285
•
•
Arsenic compounds [2006.01]
A61K 31/29
•
•
Antimony or bismuth compounds [2006.01]
A61K 31/295
•
•
Iron group metal compounds [2006.01]
A61K 31/30
•
•
Copper compounds [2006.01]
A61K 31/305
•
•
Mercury compounds [2006.01]
A61K 31/31
•
•
•
containing nitrogen [2006.01]
A61K 31/315
•
•
Zinc compounds [2006.01]
A61K 31/32
•
•
Tin compounds [2006.01]
A61K 31/325
•
Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K 31/145) [2006.01]
A61K 31/327
•
Peroxy compounds, e.g. hydroperoxides, peroxides, peroxy acids [2006.01]
A61K 31/33
•
Heterocyclic compounds [2006.01]
A61K 31/335
•
•
having oxygen as the only ring hetero atom, e.g. fungichromin [2006.01]
A61K 31/336
•
•
•
having three-membered rings, e.g. oxirane, fumagillin [2006.01]
A61K 31/337
•
•
•
having four-membered rings, e.g. taxol [2006.01]
A61K 31/34
•
•
•
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide [2006.01]
A61K 31/341
•
•
•
•
not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine [2006.01]
A61K 31/343
•
•
•
•
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone [2006.01]
A61K 31/345
•
•
•
•
Nitrofurans (nitrofurantoin A61K 31/4178) [2006.01]
A61K 31/35
•
•
•
having six-membered rings with one oxygen as the only ring hetero atom [2006.01]
A61K 31/351
•
•
•
•
not condensed with another ring [2006.01]
A61K 31/352
•
•
•
•
condensed with carbocyclic rings, e.g. cannabinols, methantheline [2006.01]
A61K 31/353
•
•
•
•
•
3,4-Dihydrobenzopyrans, e.g. chroman, catechin [2006.01]
A61K 31/355
•
•
•
•
•
•
Tocopherols, e.g. vitamin E [2006.01]
A61K 31/357
•
•
•
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel [2006.01]
A61K 31/36
•
•
•
•
Compounds containing methylenedioxyphenyl groups, e.g. sesamin [2006.01]
A61K 31/365
•
•
•
Lactones [2006.01]
A61K 31/366
•
•
•
•
having six-membered rings, e.g. delta-lactones [2006.01]
A61K 31/37
•
•
•
•
•
Coumarins, e.g. psoralen [2006.01]
A61K 31/375
•
•
•
•
Ascorbic acid, i.e. vitamin C; Salts thereof [2006.01]
A61K 31/38
•
•
having sulfur as a ring hetero atom [2006.01]
A61K 31/381
•
•
•
having five-membered rings [2006.01]
A61K 31/382
•
•
•
having six-membered rings, e.g. thioxanthenes (thiothixene A61K 31/496) [2006.01]
A61K 31/385
•
•
•
having two or more sulfur atoms in the same ring [2006.01]
A61K 31/39
•
•
•
having oxygen atoms in the same ring [2006.01]
A61K 31/395
•
•
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins (rifampin A61K 31/496) [2006.01]
A61K 31/396
•
•
•
having three-membered rings, e.g. aziridine [2006.01]
A61K 31/397
•
•
•
having four-membered rings, e.g. azetidine [2006.01]
A61K 31/40
•
•
•
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil [2006.01]
A61K 31/401
•
•
•
•
Proline; Derivatives thereof, e.g. captopril [2006.01]
A61K 31/4015
•
•
•
•
having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide [2006.01]
A61K 31/402
•
•
•
•
1-aryl-substituted, e.g. piretanide [2006.01]
A61K 31/4025
•
•
•
•
not condensed and containing further heterocyclic rings, e.g. cromakalim [2006.01]
A61K 31/403
•
•
•
•
condensed with carbocyclic rings, e.g. carbazole [2006.01]
A61K 31/4035
•
•
•
•
•
Isoindoles, e.g. phthalimide [2006.01]
A61K 31/404
•
•
•
•
•
Indoles, e.g. pindolol [2006.01]
A61K 31/4045
•
•
•
•
•
•
Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin [2006.01]
A61K 31/405
•
•
•
•
•
•
Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin [2006.01]
A61K 31/407
•
•
•
•
condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine [2006.01]
A61K 31/409
•
•
•
•
having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K 31/555) [2006.01]
A61K 31/41
•
•
•
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole [2006.01]
A61K 31/415
•
•
•
•
1,2-Diazoles [2006.01]
A61K 31/4152
•
•
•
•
•
having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone [2006.01]
A61K 31/4155
•
•
•
•
•
not condensed and containing further heterocyclic rings [2006.01]
A61K 31/416
•
•
•
•
•
condensed with carbocyclic ring systems, e.g. indazole [2006.01]
A61K 31/4162
•
•
•
•
•
condensed with heterocyclic ring systems [2006.01]
A61K 31/4164
•
•
•
•
1,3-Diazoles [2006.01]
A61K 31/4166
•
•
•
•
•
having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin [2006.01]
A61K 31/4168
•
•
•
•
•
having a nitrogen atom attached in position 2, e.g. clonidine [2006.01]
A61K 31/417
•
•
•
•
•
Imidazole-alkylamines, e.g. histamine, phentolamine [2006.01]
A61K 31/4172
•
•
•
•
•
Imidazole-alkanecarboxylic acids, e.g. histidine [2006.01]
A61K 31/4174
•
•
•
•
•
Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole [2006.01]
A61K 31/4178
•
•
•
•
•
not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin [2006.01]
A61K 31/4184
•
•
•
•
•
condensed with carbocyclic rings, e.g. benzimidazoles [2006.01]
A61K 31/4188
•
•
•
•
•
condensed with heterocyclic ring systems, e.g. biotin, sorbinil [2006.01]
A61K 31/4192
•
•
•
•
1,2,3-Triazoles [2006.01]
A61K 31/4196
•
•
•
•
1,2,4-Triazoles [2006.01]
A61K 31/42
•
•
•
•
Oxazoles [2006.01]
A61K 31/421
•
•
•
•
•
1,3-Oxazoles, e.g. pemoline, trimethadione [2006.01]
A61K 31/422
•
•
•
•
•
not condensed and containing further heterocyclic rings [2006.01]
A61K 31/423
•
•
•
•
•
condensed with carbocyclic rings [2006.01]
A61K 31/424
•
•
•
•
•
condensed with heterocyclic ring systems, e.g. clavulanic acid [2006.01]
A61K 31/4245
•
•
•
•
Oxadiazoles [2006.01]
A61K 31/425
•
•
•
•
Thiazoles [2006.01]
A61K 31/426
•
•
•
•
•
1,3-Thiazoles [2006.01]
A61K 31/427
•
•
•
•
•
not condensed and containing further heterocyclic rings [2006.01]
A61K 31/428
•
•
•
•
•
condensed with carbocyclic rings [2006.01]
A61K 31/429
•
•
•
•
•
condensed with heterocyclic ring systems [2006.01]
A61K 31/43
•
•
•
•
•
•
Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula fig604, e.g. penicillins, penems [2006.01]
A61K 31/431
•
•
•
•
•
•
•
containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin [2006.01]
A61K 31/433
•
•
•
•
Thiadiazoles [2006.01]
A61K 31/435
•
•
•
having six-membered rings with one nitrogen as the only ring hetero atom [2006.01]
A61K 31/4353
•
•
•
•
ortho- or peri-condensed with heterocyclic ring systems [2006.01]
A61K 31/4355
•
•
•
•
•
the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom [2006.01]
A61K 31/436
•
•
•
•
•
the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin [2006.01]
A61K 31/4365
•
•
•
•
•
the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine [2006.01]
A61K 31/437
•
•
•
•
•
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline [2006.01]
A61K 31/4375
•
•
•
•
•
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine [2006.01]
A61K 31/438
•
•
•
•
the ring being spiro-condensed with carbocyclic or heterocyclic ring systems [2006.01]
A61K 31/439
•
•
•
•
the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K 31/46) [2006.01]
A61K 31/44
•
•
•
•
Non-condensed pyridines; Hydrogenated derivatives thereof [2006.01]
A61K 31/4402
•
•
•
•
•
only substituted in position 2, e.g. pheniramine, bisacodyl [2006.01]
A61K 31/4406
•
•
•
•
•
only substituted in position 3, e.g. zimeldine (nicotinic acid A61K 31/455) [2006.01]
A61K 31/4409
•
•
•
•
•
only substituted in position 4, e.g. isoniazid, iproniazid [2006.01]
A61K 31/4412
•
•
•
•
•
having oxo groups directly attached to the heterocyclic ring [2006.01]
A61K 31/4415
•
•
•
•
•
Pyridoxine, i.e.vitamin B6 (pyridoxal phosphate A61K 31/675) [2006.01]
A61K 31/4418
•
•
•
•
•
having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine [2006.01]
A61K 31/4422
•
•
•
•
•
1,4-Dihydropyridines, e.g. nifedipine, nicardipine [2006.01]
A61K 31/4425
•
•
•
•
•
Pyridinium derivatives, e.g. pralidoxime, pyridostigmine [2006.01]
A61K 31/4427
•
•
•
•
•
containing further heterocyclic ring systems [2006.01]
A61K 31/443
•
•
•
•
•
•
containing a five-membered ring with oxygen as a ring hetero atom [2006.01]
A61K 31/4433
•
•
•
•
•
•
containing a six-membered ring with oxygen as a ring hetero atom [2006.01]
A61K 31/4436
•
•
•
•
•
•
containing a heterocyclic ring having sulfur as a ring hetero atom [2006.01]
A61K 31/4439
•
•
•
•
•
•
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K 31/465) [2006.01]
A61K 31/444
•
•
•
•
•
•
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone [2006.01]
A61K 31/445
•
•
•
•
•
Non-condensed piperidines, e.g. piperocaine [2006.01]
A61K 31/4453
•
•
•
•
•
•
only substituted in position 1, e.g. propipocaine, diperodon [2006.01]
A61K 31/4458
•
•
•
•
•
•
only substituted in position 2, e.g. methylphenidate [2006.01]
A61K 31/4462
•
•
•
•
•
•
only substituted in position 3 [2006.01]
A61K 31/4465
•
•
•
•
•
•
only substituted in position 4 [2006.01]
A61K 31/4468
•
•
•
•
•
•
having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl [2006.01]
A61K 31/45
•
•
•
•
•
•
having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide [2006.01]
A61K 31/451
•
•
•
•
•
•
having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine [2006.01]
A61K 31/4515
•
•
•
•
•
•
having a butyrophenone group in position 1, e.g. haloperidol (pipamperone A61K 31/4545) [2006.01]
A61K 31/452
•
•
•
•
•
•
Piperidinium derivatives (pancuronium A61K 31/58) [2006.01]
A61K 31/4523
•
•
•
•
•
•
containing further heterocyclic ring systems [2006.01]
A61K 31/4525
•
•
•
•
•
•
•
containing a five-membered ring with oxygen as a ring hetero atom [2006.01]
A61K 31/453
•
•
•
•
•
•
•
containing a six-membered ring with oxygen as a ring hetero atom [2006.01]
A61K 31/4535
•
•
•
•
•
•
•
containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen [2006.01]
A61K 31/454
•
•
•
•
•
•
•
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone [2006.01]
A61K 31/4545
•
•
•
•
•
•
•
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine [2006.01]
A61K 31/455
•
•
•
•
•
Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides [2006.01]
A61K 31/46
•
•
•
•
8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine [2006.01]
A61K 31/465
•
•
•
•
Nicotine; Derivatives thereof [2006.01]
A61K 31/47
•
•
•
•
Quinolines; Isoquinolines [2006.01]
A61K 31/4704
•
•
•
•
•
2-Quinolinones, e.g. carbostyril [2006.01]
A61K 31/4706
•
•
•
•
•
4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine [2006.01]
A61K 31/4709
•
•
•
•
•
Non-condensed quinolines containing further heterocyclic rings [2006.01]
A61K 31/472
•
•
•
•
•
Non-condensed isoquinolines, e.g. papaverine [2006.01]
A61K 31/4725
•
•
•
•
•
•
containing further heterocyclic rings [2006.01]
A61K 31/473
•
•
•
•
•
ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines [2006.01]
A61K 31/4738
•
•
•
•
•
ortho- or peri-condensed with heterocyclic ring systems [2006.01]
A61K 31/4741
•
•
•
•
•
•
condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline [2006.01]
A61K 31/4743
•
•
•
•
•
•
condensed with ring systems having sulfur as a ring hetero atom [2006.01]
A61K 31/4745
•
•
•
•
•
•
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines (yohimbine derivatives, vinblastine A61K 31/475; ergoline derivatives A61K 31/48) [2006.01]
A61K 31/4747
•
•
•
•
•
spiro-condensed [2006.01]
A61K 31/4748
•
•
•
•
•
forming part of bridged ring systems (strychnine A61K 31/475; morphinan derivatives A61K 31/485) [2006.01]
A61K 31/475
•
•
•
•
•
having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K 31/4375) [2006.01]
A61K 31/48
•
•
•
•
•
Ergoline derivatives, e.g. lysergic acid, ergotamine [2006.01]
A61K 31/485
•
•
•
•
•
Morphinan derivatives, e.g. morphine, codeine [2006.01]
A61K 31/49
•
•
•
•
•
Cinchonan derivatives, e.g. quinine [2006.01]
A61K 31/495
•
•
•
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine (A61K 31/48 takes precedence) [2006.01]
A61K 31/496
•
•
•
•
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene [2006.01]
A61K 31/4965
•
•
•
•
Non-condensed pyrazines [2006.01]
A61K 31/497
•
•
•
•
•
containing further heterocyclic rings [2006.01]
A61K 31/498
•
•
•
•
Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine [2006.01]
A61K 31/4985
•
•
•
•
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems [2006.01]
A61K 31/499
•
•
•
•
Spiro-condensed pyrazines or piperazines [2006.01]
A61K 31/4995
•
•
•
•
Pyrazines or piperazines forming part of bridged ring systems [2006.01]
A61K 31/50
•
•
•
•
Pyridazines; Hydrogenated pyridazines [2006.01]
A61K 31/501
•
•
•
•
•
not condensed and containing further heterocyclic rings [2006.01]
A61K 31/502
•
•
•
•
•
ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine [2006.01]
A61K 31/5025
•
•
•
•
•
ortho- or peri-condensed with heterocyclic ring systems [2006.01]
A61K 31/503
•
•
•
•
•
spiro-condensed [2006.01]
A61K 31/504
•
•
•
•
•
forming part of bridged ring systems [2006.01]
A61K 31/505
•
•
•
•
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim [2006.01]
A61K 31/506
•
•
•
•
•
not condensed and containing further heterocyclic rings [2006.01]
A61K 31/51
•
•
•
•
•
•
Thiamines, e.g. vitamin B1 [2006.01]
A61K 31/513
•
•
•
•
•
having oxo groups directly attached to the heterocyclic ring, e.g. cytosine [2006.01]
A61K 31/515
•
•
•
•
•
•
Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital [2006.01]
A61K 31/517
•
•
•
•
•
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine [2006.01]
A61K 31/519
•
•
•
•
•
ortho- or peri-condensed with heterocyclic rings [2006.01]
A61K 31/52
•
•
•
•
•
•
Purines, e.g. adenine [2006.01]
A61K 31/522
•
•
•
•
•
•
•
having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir [2006.01]
A61K 31/525
•
•
•
•
•
•
Isoalloxazines, e.g. riboflavins, vitamin B2 [2006.01]
A61K 31/527
•
•
•
•
•
spiro-condensed [2006.01]
A61K 31/529
•
•
•
•
•
forming part of bridged ring systems [2006.01]
A61K 31/53
•
•
•
having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K 31/555) [2006.01]
A61K 31/535
•
•
•
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines [2006.01]
A61K 31/5355
•
•
•
•
Non-condensed oxazines containing further heterocyclic rings [2006.01]
A61K 31/536
•
•
•
•
ortho- or peri-condensed with carbocyclic ring systems [2006.01]
A61K 31/5365
•
•
•
•
ortho- or peri-condensed with heterocyclic ring systems [2006.01]
A61K 31/537
•
•
•
•
spiro-condensed or forming part of bridged ring systems [2006.01]
A61K 31/5375
•
•
•
•
1,4-Oxazines, e.g. morpholine [2006.01]
A61K 31/5377
•
•
•
•
•
not condensed and containing further heterocyclic rings, e.g. timolol [2006.01]
A61K 31/538
•
•
•
•
•
ortho- or peri-condensed with carbocyclic ring systems [2006.01]
A61K 31/5383
•
•
•
•
•
ortho- or peri-condensed with heterocyclic ring systems [2006.01]
A61K 31/5386
•
•
•
•
•
spiro-condensed or forming part of bridged ring systems [2006.01]
A61K 31/539
•
•
•
•
having two or more oxygen atoms in the same ring, e.g dioxazines [2006.01]
A61K 31/5395
•
•
•
•
having two or more nitrogen atoms in the same ring, e.g. oxadiazines [2006.01]
A61K 31/54
•
•
•
having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame [2006.01]
A61K 31/541
•
•
•
•
Non-condensed thiazines containing further heterocyclic rings [2006.01]
A61K 31/5415
•
•
•
•
ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam [2006.01]
A61K 31/542
•
•
•
•
ortho- or peri-condensed with heterocyclic ring systems [2006.01]
A61K 31/545
•
•
•
•
•
Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula fig605, e.g. cephalosporins, cefaclor, cephalexine [2006.01]
A61K 31/546
•
•
•
•
•
•
containing further heterocyclic rings, e.g. cephalothin [2006.01]
A61K 31/547
•
•
•
•
spiro-condensed or forming part of bridged ring systems [2006.01]
A61K 31/548
•
•
•
•
having two or more sulfur atoms in the same ring [2006.01]
A61K 31/549
•
•
•
•
having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide [2006.01]
A61K 31/55
•
•
•
having seven-membered rings, e.g. azelastine, pentylenetetrazole [2006.01]
A61K 31/551
•
•
•
•
having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep [2006.01]
A61K 31/5513
•
•
•
•
•
1,4-Benzodiazepines, e.g. diazepam [2006.01]
A61K 31/5517
•
•
•
•
•
•
condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam [2006.01]
A61K 31/553
•
•
•
•
having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine [2006.01]
A61K 31/554
•
•
•
•
having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem [2006.01]
A61K 31/555
•
•
containing heavy metals, e.g. hemin, hematin, melarsoprol [2006.01]
A61K 31/557
•
Eicosanoids, e.g. leukotrienes [2006.01]
A61K 31/5575
•
•
having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha [2006.01]
A61K 31/5578
•
•
having a pentalene ring system, e.g. carbacyclin, iloprost [2006.01]
A61K 31/558
•
•
having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes [2006.01]
A61K 31/5585
•
•
•
having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin [2006.01]
A61K 31/559
•
•
having heterocyclic rings containing hetero atoms other than oxygen [2006.01]
A61K 31/56
•
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids [2006.01]
•

Note(s) [7]

  • Attention is drawn to Note (1) following the title of subclass C07J, which explains what is covered by the term "steroids".
A61K 31/565
•
•
not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol [2006.01]
A61K 31/566
•
•
•
having an oxo group in position 17, e.g. oestrone [2006.01]
A61K 31/567
•
•
•
substituted in position 17 alpha, e.g. mestranol, norethandrolone [2006.01]
A61K 31/568
•
•
•
substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone [2006.01]
A61K 31/5685
•
•
•
•
having an oxo group in position 17, e.g. androsterone [2006.01]
A61K 31/569
•
•
•
•
substituted in position 17 alpha, e.g. ethisterone [2006.01]
A61K 31/57
•
•
substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone [2006.01]
A61K 31/573
•
•
•
substituted in position 21, e.g. cortisone, dexamethasone, prednisone [2006.01]
A61K 31/575
•
•
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol [2006.01]
A61K 31/58
•
•
containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin (digitoxin A61K 31/704) [2006.01]
A61K 31/585
•
•
•
containing lactone rings, e.g. oxandrolone, bufalin [2006.01]
A61K 31/59
•
Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems [2006.01]
A61K 31/592
•
•
9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2 [2006.01]
A61K 31/593
•
•
9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3 [2006.01]
A61K 31/60
•
Salicylic acid; Derivatives thereof [2006.01]
A61K 31/603
•
•
having further aromatic rings, e.g. diflunisal [2006.01]
A61K 31/606
•
•
having amino groups [2006.01]
A61K 31/609
•
•
Amides, e.g. salicylamide [2006.01]
A61K 31/612
•
•
having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid (fosfosal A61K 31/661) [2006.01]
A61K 31/616
•
•
•
by carboxylic acids, e.g. acetylsalicylic acid [2006.01]
A61K 31/618
•
•
having the carboxyl group in position 1 esterified, e.g. salsalate [2006.01]
A61K 31/621
•
•
•
having the hydroxy group in position 2 esterified, e.g. benorylate [2006.01]
A61K 31/625
•
•
having heterocyclic substituents, e.g. 4-salicyloylmorpholine (sulfasalazine A61K 31/635) [2006.01]
A61K 31/63
•
Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide [2006.01]
A61K 31/635
•
•
having a heterocyclic ring, e.g. sulfadiazine [2006.01]
A61K 31/64
•
Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide [2006.01]
A61K 31/65
•
Tetracyclines [2006.01]
A61K 31/655
•
Azo (—N=N—), diazo (=N2), azoxy (llinktN—O—Nrlinkt or N(=O)—Nrlinkt), azido (—N3) or diazoamino (—N=N—Nrlinkt) compounds [2006.01]
A61K 31/66
•
Phosphorus compounds [2006.01]
A61K 31/661
•
•
Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion [2006.01]
A61K 31/6615
•
•
•
Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid [2006.01]
A61K 31/662
•
•
Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon [2006.01]
A61K 31/663
•
•
•
Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid [2006.01]
A61K 31/664
•
•
Amides of phosphorus acids [2006.01]
A61K 31/665
•
•
having oxygen as a ring hetero atom, e.g. fosfomycin [2006.01]
A61K 31/67
•
•
having sulfur as a ring hetero atom [2006.01]
A61K 31/675
•
•
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate [2006.01]
A61K 31/683
•
•
Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols [2006.01]
A61K 31/685
•
•
•
one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin [2006.01]
A61K 31/688
•
•
•
both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins [2006.01]
A61K 31/69
•
Boron compounds [2006.01]
A61K 31/695
•
Silicon compounds [2006.01]
A61K 31/70
•
Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K 31/047) [2006.01]
•

Note(s) [7]

  • In this group, the expressions are used with the meanings indicated in Note (3) following the title of subclass C07H.
A61K 31/7004
•
•
Monosaccharides having only carbon, hydrogen and oxygen atoms [2006.01]
A61K 31/7008
•
•
Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine [2006.01]
A61K 31/7012
•
•
Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K 31/191; ascorbic acid A61K 31/375) [2006.01]
A61K 31/7016
•
•
Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K 31/7032) [2006.01]
A61K 31/702
•
•
Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages [2006.01]
A61K 31/7024
•
•
Esters of saccharides [2006.01]
A61K 31/7028
•
•
Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages [2006.01]
A61K 31/7032
•
•
•
attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides [2006.01]
A61K 31/7034
•
•
•
attached to a carbocyclic compound, e.g. phloridzin [2006.01]
A61K 31/7036
•
•
•
•
having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins [2006.01]
A61K 31/704
•
•
•
•
attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin [2006.01]
A61K 31/7042
•
•
Compounds having saccharide radicals and heterocyclic rings [2006.01]
A61K 31/7048
•
•
•
having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin [2006.01]
A61K 31/7052
•
•
•
having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides [2006.01]
A61K 31/7056
•
•
•
•
containing five-membered rings with nitrogen as a ring hetero atom [2006.01]
A61K 31/706
•
•
•
•
containing six-membered rings with nitrogen as a ring hetero atom [2006.01]
A61K 31/7064
•
•
•
•
•
containing condensed or non-condensed pyrimidines [2006.01]
A61K 31/7068
•
•
•
•
•
•
having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid [2006.01]
A61K 31/7072
•
•
•
•
•
•
•
having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine [2006.01]
A61K 31/7076
•
•
•
•
•
•
containing purines, e.g. adenosine, adenylic acid [2006.01]
A61K 31/708
•
•
•
•
•
•
•
having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid [2006.01]
A61K 31/7084
•
•
Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide [2006.01]
A61K 31/7088
•
•
Compounds having three or more nucleosides or nucleotides [2006.01]
A61K 31/7105
•
•
•
Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links [2006.01]
A61K 31/711
•
•
•
Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links [2006.01]
A61K 31/7115
•
•
•
Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine [2006.01]
A61K 31/712
•
•
•
Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose [2006.01]
A61K 31/7125
•
•
•
Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters [2006.01]
A61K 31/713
•
•
•
Double-stranded nucleic acids or oligonucleotides [2006.01]
A61K 31/7135
•
•
Compounds containing heavy metals [2006.01]
A61K 31/714
•
•
•
Cobalamins, e.g. cyanocobalamin, vitamin B12 [2006.01]
A61K 31/715
•
•
Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters [2006.01]
A61K 31/716
•
•
•
Glucans [2006.01]
A61K 31/717
•
•
•
•
Celluloses [2006.01]
A61K 31/718
•
•
•
•
Starch or degraded starch, e.g. amylose, amylopectin [2006.01]
A61K 31/719
•
•
•
•
Pullulans [2006.01]
A61K 31/721
•
•
•
•
Dextrans [2006.01]
A61K 31/722
•
•
•
•
Chitin; Chitosan [2006.01]
A61K 31/723
•
•
•
•
Xanthans [2006.01]
A61K 31/724
•
•
•
•
Cyclodextrins [2006.01]
A61K 31/726
•
•
•
Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K 31/737) [2006.01]
A61K 31/727
•
•
•
•
Heparin; Heparan [2006.01]
A61K 31/728
•
•
•
•
Hyaluronic acid [2006.01]
A61K 31/729
•
•
•
Agar; Agarose; Agaropectin [2006.01]
A61K 31/731
•
•
•
Carrageenans [2006.01]
A61K 31/732
•
•
•
Pectin [2006.01]
A61K 31/733
•
•
•
Fructosans, e.g. inulin [2006.01]
A61K 31/734
•
•
•
Alginic acid [2006.01]
A61K 31/736
•
•
•
Glucomannans or galactomannans, e.g locust bean gum, guar gum [2006.01]
A61K 31/737
•
•
•
Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K 31/727 takes precedence) [2006.01]
A61K 31/738
•
•
•
Cross-linked polysaccharides [2006.01]
A61K 31/739
•
•
•
Lipopolysaccharides [2006.01]
A61K 31/74
•
Synthetic polymeric materials [2006.01]
A61K 31/745
•
•
Polymers of hydrocarbons [2006.01]
A61K 31/75
•
•
•
of ethene [2006.01]
A61K 31/755
•
•
Polymers containing halogen [2006.01]
A61K 31/76
•
•
•
of vinyl chloride [2006.01]
A61K 31/765
•
•
Polymers containing oxygen [2006.01]
A61K 31/77
•
•
•
of oxiranes [2006.01]
A61K 31/775
•
•
•
Phenolic resins [2006.01]
A61K 31/78
•
•
•
of acrylic acid or derivatives thereof [2006.01]
A61K 31/785
•
•
Polymers containing nitrogen [2006.01]
A61K 31/787
•
•
•
containing heterocyclic rings having nitrogen as a ring hetero atom [2006.01]
A61K 31/79
•
•
•
•
Polymers of vinyl pyrrolidone [2006.01]
A61K 31/795
•
•
Polymers containing sulfur [2006.01]
A61K 31/80
•
•
Polymers containing hetero atoms not provided for in groups A61K 31/755-A61K 31/795 [2006.01]
A61K 33/00
Medicinal preparations containing inorganic active ingredients [2006.01]
A61K 33/02
•
Ammonia; Compounds thereof [2006.01]
A61K 33/04
•
Sulfur, selenium or tellurium; Compounds thereof [2006.01]
A61K 33/06
•
Aluminium, calcium or magnesium; Compounds thereof [2006.01]
A61K 33/08
•
•
Oxides; Hydroxides [2006.01]
A61K 33/10
•
•
Carbonates; Bicarbonates [2006.01]
A61K 33/12
•
•
Magnesium silicate [2006.01]
A61K 33/14
•
Alkali metal chlorides; Alkaline earth metal chlorides [2006.01]
A61K 33/16
•
Fluorine compounds [2006.01]
A61K 33/18
•
Iodine; Compounds thereof [2006.01]
A61K 33/20
•
Elemental chlorine; Inorganic compounds releasing chlorine [2006.01]
A61K 33/22
•
Boron compounds [2006.01]
A61K 33/24
•
Heavy metals; Compounds thereof [2006.01]
A61K 33/26
•
•
Iron; Compounds thereof [2006.01]
A61K 33/28
•
•
Mercury; Compounds thereof [2006.01]
A61K 33/30
•
•
Zinc; Compounds thereof [2006.01]
A61K 33/32
•
•
Manganese; Compounds thereof [2006.01]
A61K 33/34
•
•
Copper; Compounds thereof [2006.01]
A61K 33/36
•
•
Arsenic; Compounds thereof [2006.01]
A61K 33/38
•
•
Silver; Compounds thereof [2006.01]
A61K 33/40
•
Peroxides [2006.01]
A61K 33/42
•
Phosphorus; Compounds thereof [2006.01]
A61K 33/44
•
Elemental carbon, e.g. charcoal, carbon black [2006.01]
A61K 35/00
Medicinal preparations containing materials or reaction products thereof with undetermined constitution [2006.01]

Note(s) [2015.01]

  • In this group, classification is made for each active component or material. For each active component or material, classification is then made in the last appropriate place.
  • When classifying in this group, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.
A61K 35/02
•
from inanimate materials (carbon A61K 33/44) [2015.01]
A61K 35/04
•
•
Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate [2006.01]
A61K 35/06
•
•
•
Mineral oils, e.g. paraffinic oils or aromatic oils based on aromatic hydrocarbons [2006.01]
A61K 35/08
•
•
Mineral waters; Seawater [2015.01]
A61K 35/10
•
•
Peat; Amber; Turf; Humus [2015.01]
A61K 35/12
•
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (uncharacterised stem cells A61K 35/545; vaccines or medicinal preparations containing antigens or antibodies A61K 39/00) [2015.01]
•

Note(s) [2015.01]

  • If the cells are characterised, classification is made in the group covering the corresponding tissue or tissue of origin.
A61K 35/13
•
•
Tumour cells, irrespective of tissue of origin (tumour vaccines A61K 39/00) [2015.01]
A61K 35/14
•
•
Blood; Artificial blood (perfluorocarbons A61K 31/02; umbilical cord blood A61K 35/51; haemoglobin A61K 38/42) [2015.01]
A61K 35/15
•
•
•
Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K 39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K 39/00) [2015.01]
A61K 35/16
•
•
•
Blood plasma; Blood serum (umbilical cord blood A61K 35/51) [2015.01]
A61K 35/17
•
•
•
Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K 39/00) [2015.01]
A61K 35/18
•
•
•
Erythrocytes (haemoglobin A61K 38/42) [2015.01]
A61K 35/19
•
•
•
Platelets; Megacaryocytes [2015.01]
A61K 35/20
•
•
Milk; Whey; Colostrum [2006.01]
A61K 35/22
•
•
Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland [2015.01]
A61K 35/23(transferred to A61K 35/22, A61K 35/57)
A61K 35/24
•
•
Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid (saliva A61K 35/38) [2015.01]
A61K 35/26
•
•
Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes [2015.01]
A61K 35/28
•
•
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells [2015.01]
A61K 35/30
•
•
Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue [2015.01]
A61K 35/32
•
•
Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane [2015.01]
A61K 35/33
•
•
Fibroblasts [2015.01]
A61K 35/34
•
•
Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K 35/44) [2015.01]
A61K 35/35
•
•
Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K 35/28; collagen A61K 38/39) [2015.01]
A61K 35/36
•
•
Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K 35/39) [2015.01]
A61K 35/37
•
•
Digestive system [2015.01]
A61K 35/38
•
•
•
Stomach; Intestine; Goblet cells; Oral mucosa; Saliva [2015.01]
A61K 35/39
•
•
•
Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K 35/36) [2015.01]
A61K 35/407
•
•
•
Liver; Hepatocytes [2015.01]
A61K 35/413
•
•
•
Gall bladder; Bile [2015.01]
A61K 35/42
•
•
Respiratory system, e.g. lungs, bronchi or lung cells [2015.01]
A61K 35/44
•
•
Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells [2015.01]
A61K 35/48
•
•
Reproductive organs [2015.01]
A61K 35/50
•
•
•
Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells [2015.01]
A61K 35/51
•
•
•
Umbilical cord; Umbilical cord blood; Umbilical stem cells [2015.01]
A61K 35/52
•
•
•
Sperm; Prostate; Seminal fluid; Leydig cells of testes [2015.01]
A61K 35/54
•
•
•
Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells [2015.01]
A61K 35/545
•
•
•
•
Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells [2015.01]
A61K 35/55
•
•
Glands not provided for in groups A61K 35/22-A61K 35/545, e.g. thyroids, parathyroids or pineal glands [2015.01]
A61K 35/56
•
Materials from animals other than mammals [2015.01]
A61K 35/57
•
•
Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli [2015.01]
A61K 35/58
•
•
Reptiles (antigens from snakes  A61K 39/38) [2015.01]
A61K 35/583
•
•
•
Snakes; Lizards, e.g. chameleons (therapeutic use of a snake venom protein A61K 38/00) [2015.01]
A61K 35/586
•
•
•
Turtles; Tortoises, e.g. terrapins [2015.01]
A61K 35/60
•
•
Fish, e.g. seahorses; Fish eggs [2006.01]
A61K 35/612
•
•
Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles [2015.01]
A61K 35/614
•
•
Cnidaria, e.g. sea anemones, corals, coral animals or jellyfish [2015.01]
A61K 35/616
•
•
Echinodermata, e.g. starfish, sea cucumbers or sea urchins [2015.01]
A61K 35/618
•
•
Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs [2015.01]
A61K 35/62
•
•
Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia [2006.01]
A61K 35/63
•
•
Arthropods (aquatic crustaceans A61K 35/612) [2015.01]
A61K 35/64
•
•
•
Insects, e.g. bees, wasps or fleas [2015.01]
A61K 35/644
•
•
•
•
Beeswax; Propolis; Royal jelly; Honey [2015.01]
A61K 35/646
•
•
•
Arachnids, e.g. spiders, scorpions, ticks or mites [2015.01]
A61K 35/648
•
•
•
Myriapods, e.g. centipedes or millipedes [2015.01]
A61K 35/65
•
•
Amphibians, e.g. toads, frogs, salamanders or newts [2015.01]
A61K 35/655
•
•
Aquatic animals other than those covered by groups A61K 35/57-A61K 35/65 [2015.01]
A61K 35/66
•
Micro-organisms or materials therefrom (fungi, yeasts or candida A61K 36/06) [2015.01]
A61K 35/68
•
•
Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma [2006.01]
A61K 35/74
•
•
Bacteria (therapeutic use of a bacterial protein A61K 38/00) [2015.01]
A61K 35/741
•
•
•
Probiotics (probiotic yeast, e.g. saccharomyces A61K 36/06) [2015.01]
A61K 35/742
•
•
•
•
Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes [2015.01]
A61K 35/744
•
•
•
•
Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs [2015.01]
A61K 35/745
•
•
•
•
•
Bifidobacteria [2015.01]
A61K 35/747
•
•
•
•
•
Lactobacilli, e.g. L. acidophilus or L. brevis [2015.01]
A61K 35/748
•
•
•
Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina (algae, microalgae or microphytes A61K 36/02) [2015.01]
A61K 35/76
•
•
Viruses; Subviral particles; Bacteriophages [2015.01]
A61K 35/761
•
•
•
Adenovirus [2015.01]
A61K 35/763
•
•
•
Herpes virus [2015.01]
A61K 35/765
•
•
•
Reovirus; Rotavirus [2015.01]
A61K 35/766
•
•
•
Rhabdovirus, e.g. vesicular stomatitis virus [2015.01]
A61K 35/768
•
•
•
Oncolytic viruses not provided for in groups A61K 35/761-A61K 35/766 [2015.01]
A61K 41/00
Medicinal preparations obtained by treating materials with wave energy or particle radiation (A61K 31/59 takes precedence) [2006.01]
A61K 48/00
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy [2006.01]
A61K 50/00
Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ECG) or for transcutaneous drug administration [2006.01]
Indexing scheme associated with group A61K 51/00, relating to the nature of the radioactive substance. [6]
Indexing scheme associated with group A61K 36/00, relating to plant parts with medicinal activity. [2006.01]
A61K 125/00
Containing or obtained from roots, bulbs, tubers, corms or rhizomes [2006.01]
A61K 127/00
Containing or obtained from leaves [2006.01]
A61K 129/00
Containing or obtained from bark [2006.01]
A61K 131/00
Containing or obtained from seeds, nuts, fruits or grains [2006.01]
A61K 133/00
Containing or obtained from flowers or blossoms [2006.01]
A61K 135/00
Containing or obtained from stems, stalks, branches, twigs or shoots [2006.01]